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BACKGROUND: To determine the mechanisms associated with loss of androgen dependency and disease progression in prostate
cancer (PCa), we investigated the relationship between the androgen receptor (AR) and mTOR pathways and the impact of
inhibiting both pathways in androgen-dependent and castration-resistant PCa models.
EXPERIMENTAL DESIGN: Androgen-dependent (LNCaP) and castration-resistant PCa (HP-LNCaP) cells were grown as tumours in SCID
mice. Once tumours reached 500mm
3, animals were grouped and injected subcutaneous with vehicle, our novel anti-androgen/
androgen synthesis inhibitor, VN/124-1, bicalutamide, and everolimus. Tumour volumes were measured biweekly. The PSA and
protein analyses were performed after completion of the treatment.
RESULTS: The addition of everolimus to bicalutamide treatment of resistant tumours significantly reduced tumour growth rates and
tumour volumes. Anti-androgen treatment also increased protein expression of multiple signal transduction pathways earlier than
vehicle-treated control xenografts. VN/124-1 plus everolimus acted in concert to reduce tumour growth rates in our castration-
resistant xenograft model.
CONCLUSIONS: This study suggests that dual inhibition of AR and mTOR in castration-resistant xenograft models can restore sensitivity
of tumours to anti-androgen therapy. Furthermore, after bicalutamide failure, dual inhibition with VN/124-1 and everolimus was the
most effective treatment.
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The progression to castration-resistant prostrate cancer (CRPC)
requires the ability to overcome two major roadblocks, the initial
survival of prostate cancer (PCa) cells during the acute onset of
androgen deprivation and the ability to proliferate in a castrate-
independent manner. During castrate-resistant progression, PCa
cells adapt to alternative cellular signalling to survive in an
androgen-depleted environment.
The lack of successful treatments for CRPC is, in part, a
reflection of the poor understanding of the mechanisms and
pathways that lead to increased cell survival after androgen
ablation. Several mechanisms and pathways have been proposed to
explain castrate resistance. The two main mechanisms of progres-
sion are those that involve the androgen receptor (AR) and those
that bypass the AR. However, these pathways are not mutually
exclusive, and cross-talk between the AR and signal transduction
pathways (STPs) in CRPC has been demonstrated (Baron et al,
2004; Cinar et al, 2005; Culig et al, 2005; Ghosh et al, 2005;
Edwards and Bartlett, 2005a,b).
We and others have shown that PCa cells can become
hypersensitive to androgens as a means of circumventing
androgen blockade (Gregory et al, 2001a,b). Hypersensitivity is
believed to be caused by an increase in AR expression, which is a
result of AR gene amplification (Visakorpi et al, 1995; Linja et al,
2001; Edwards et al, 2003; Chen et al, 2004). Koivisto et al (1997)
originally showed that AR amplification contributed directly to the
failure of androgen deprivation by allowing cells to grow in low
concentrations of androgen, resulting in hypersensitivity (Gregory
et al, 2001a,b). Numerous studies have shown that despite the
elimination of testicular androgens, the level of T and DHT in
recurrent PCa tissue is unchanged relative to levels in benign tissue
(Mohler et al, 2004; Titus et al, 2005). Intraprostatic androgen
concentrations are therefore likely to be more precise indicators of
the tumour environment than serum hormone levels (Habib et al,
1976; Heracek et al, 2007). Furthermore, it has been shown that
DHT levels in prostatic tissue of castrated patients are sufficient to
activate the AR and stimulate expression of androgen-regulated
genes (Culig et al, 1999; Mohler et al, 2004; Mostaghel et al, 2007).
The exact mechanisms of steroids in promoting proliferation in
CRPC remain unclear. However, there is increasing evidence to
suggest that compensatory signalling mechanisms and cross-talk
occur between growth factor receptor pathways and AR in
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sandrogen-dependent and CRPC cell lines. Recent investigations
have elucidated multiple mechanisms for regulation of AR by
STPs and vice versa (Cinar et al, 2005; Yang et al, 2005). Several
mechanisms of cross-talk have been reported between the AR and
P13K/Akt/mTOR signalling pathway. Indeed, we have previously
reported that the P13K/Akt/mTOR pathway is upregulated in
LNCaP and HP-LNCaP cells (Schayowitz et al, 2008). Although the
specific therapeutic impact is unknown, synergy between AR
antagonists and P13K/Akt/mTOR inhibitors further suggests a
functional relationship between the two pathways (Lin et al, 1999,
2001, 2004; Manin et al, 2002; Sun et al, 2003; Festuccia et al, 2005;
Yang et al, 2005; Schayowitz et al, 2008).
From our previous in vitro findings (Schayowitz et al, 2008), we
concluded that growth factor receptor pathways, specifically P13K/
Akt/mTOR, are upregulated as LNCaP androgen-dependent cells
adapt to become castrate resistant. We found that blocking both
pathways with AR plus mTOR inhibitors was more effective that
either inhibitor alone in reducing proliferation (Schayowitz et al,
2008). In this report, we have investigated whether tumour growth
of apparent castrate-resistant tumours could be effectively
inhibited by combining an mTOR inhibitor (everolimus, RAD-001,
a rapamycin analogue inhibitor that blocks the downstream
signalling cascade in vitro and in vivo (Boulay et al, 2004; Vignot
et al, 2005)) with our novel compound VN/124-1. VN/124-1 is a
potent inhibitor of CYP17 and reduces androgen synthesis. It also
binds to the AR and causes its degradation. VN/124-1 is at least as
effective as current anti-androgens in androgen-dependent PCa
cell lines and significantly more effective in CRPC cells. Combined
with inhibitors of STPs, this compound may be an effective
strategy for treatment of CRPC (Schayowitz et al, 2008).
MATERIALS AND METHODS
Materials
RPMI, T-medium, penicillin/streptomycin solution (10000IU
each), 0.25% trypsin-EDTA (1mmoll
 1) solution, and Dulbecco’s
phosphate-buffered saline were obtained from Invitrogen (Carls-
bad, CA, USA). Regular serum and charcoal-stripped fetal bovine
serum (FBS) were obtained from Hyclone (Logan, UT, USA). The
C4-2B cells were kindly supplied by Dr Yun Qiu (University of
Maryland, Baltimore, MD, USA). Dimethyl sulfoxide (DMSO),
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
and Tween 20 were obtained from Sigma Chemicals Company
(St. Louis, MO, USA). The ECL chemiluminescence kit and Hybond-
ECL nitrocellulose membranes were purchased from Amersham
Biosciences (Piscataway, NJ, USA). Antibodies against p-Akt
(Ser-473 and Thr-308), p-mTOR (Ser2448 and Ser2481), p-MAPK,
IGFR1, p-P70S6K, p-PS6, immobilised Akt, and b-actin were
purchased from Cell Signaling Technology, Beverly, MA, USA. The
p-HER2 was purchased from Upstate (Temecula, CA, USA) and AR
(SC-441) was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The total PSA ELISA kit was purchased from Diagnostic
Systems Laboratories in Webster (TX, USA). Bicalutamide (Casodex)
was kindly provided by Dr Elizabeth Anderson (Astra Zeneca,
Macclesfield, UK). Everolimus (42-O-(2-hydroxy) ethyl-rapamycin)
(RAD-001) was kindly provided by Dr D Evans (Novartis Pharma-
ceuticals, Basel, Switzerland), and dissolved in 100% DMSO for cell
culture application. Novel compound VN/124-1 (3b-hydroxy-17-(1H-
benzimidazol-1-yl)androsta-5,16-diene) was designed and synthesised
by one of us, Dr Vincent CO Njar (Handratta et al, 2005).
Cell culture
Androgen-dependent PCa cells derived from metastatic lymph
node of a PCa patient (LNCaP) were routinely maintained in RPMI
1640 medium with 10% FBS and 1% penicillin/streptomycin
solution (Horoszewicz et al, 1983). The CRPC (HP-LNCaP) cells
were created through regular passaging of the LNCaP cell line for
more than 1 year, as previously described and characterised
(Schayowitz et al, 2008). Low-passage LNCaP cells (LNCaP) were
designated as under passage 25, whereas high-passage cells
(HP-LNCaP) were over passage 75. Both lines were maintained
in identical conditions. The CRPC in vivo-derived cell line from
LNCaP cells (C4-2B) were maintained in T-Medium with 10% FBS
and 1% penicillin/streptomycin (Thalmann et al, 1994, 2000).
Cell growth studies
MTT proliferation assays were performed to examine the effect of
R1881, a synthetic, non-metabolised androgen, on cell prolifera-
tion in LNCaP and HP-LNCaP cell lines. The IC50 values for
inhibition were calculated via non-linear regression. All growth
studies involving anti-androgen were performed in the presence of
0.1nM R1881.
Western blotting
The protein extracts from tumours were prepared by pelleting
homogenised tissue suspended in ice-cold DPBS and lysed with
cell lysis buffer containing protease inhibitors, Tris-CL, and Triton
X-100. Equal amounts (50mg) of protein from each sample were
separated on a denaturing polyacrylamide gel, transferred to
nitrocellulose membrane, and western blotting was carried as
previously described (Schayowitz et al, 2008). The densitometric
values are corrected for loading control shown in the bottom panel
of the figures. All western blots were performed at least two times;
blots shown are representative of all results.
PSA ELISA
Tissue lysates and serum were loaded in the total PSA ELISA Kit
(DSLabs, Webster, TX, USA) in triplicates to determine PSA
concentrations. The assay standards, controls, and samples were
incubated in 96-well plates following the manufacturer’s instruc-
tions. Each original experimental sample was assayed in triplicate.
The PSA values (ngml
 1) were determined using log–log curve fit
to the standard curve.
Tumour growth in male SCID mice
All animal studies were performed according to the guidelines and
approval of the Animal Care Committee of the University of
Maryland School of Medicine. Male SCID mice 4–6 weeks of age
were obtained from the National Cancer Institute-Frederick Cancer
Research Center (Frederick, MD, USA). The mice were housed in a
pathogen-free environment under controlled conditions of light
and humidity and received food and water ad libitum. The mice
were inoculated with LNCaP or HP-LNCaP cells. These in vivo
studies were performed using two PCa cell lines. Androgen-
dependent cells, designated as LNCaP cells, and androgen-
independent cells, denoted as HP-LNCaP cells (Schayowitz et al,
2008), were inoculated into male SCID mice and formed tumours.
The mice were then treated with a combination of inhibitors to
block the AR and mTOR activation. The cells were grown in
regular growth conditions (RPMI, 10% FBS and 1% penicillin/
streptomycin). Subconfluent cells were scrapped into DPBS,
collected by centrifugation, and resuspended in Matrigel
(10mgml
 1) at 2.0 10
7cells per ml. Each mouse received a
subcutaneous (s.c.) inoculation at one site per flank with 100mlo f
cell suspension. Tumour formation varied between 4 and 8 weeks
by cell line, although on tumours reaching 500mm
3, mice were
grouped by 5 or 10 with equal tumour volumes. Tumour size was
measured twice weekly with calipers, and tumour volume was
calculated by the formula 4/3pr1
2 r2, where r1 is the smaller
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sradius. Treatments varied between 3 and 7 weeks by experiment.
All mice were killed by decapitation under anaesthesia, and the
trunk blood was collected for PSA analysis. Tumours were also
excised, cleaned, weighed, and stored in  801C for additional
analysis.
Statistics
Data on tumour volume and weight were analysed separately.
Growth curve models were used to summarise the pattern of
response over treatment duration. The tumour growth rate (the
slope of regression line) was compared between pre-specified
treatment groups. The mean tumour volume was modelled as a
combination of fixed effects shared by all subjects and random
effects unique to a particular animal. We used random effects for
both intercept and slope at the animal level. The proportions of
tumours that shrunk below a threshold during treatment
were compared using Fisher’s exact test. The treatment groups
were compared with one another at 0.05 level of statistical
significance. All reported P-values were two sided. Mixed-effects
models were used to compare average tumour volume on pre-
specified time points. The Tukey–Kramer method was used to
adjust for multiple comparisons.
RESULTS
In vitro effects of androgens on LNCaP and HP-LNCaP
As we previously reported, the proliferation of HP-LNCaP cells was
significantly greater than that of LNCaP cells in the presence and
absence of steroids (Schayowitz et al, 2008). The LNCaP cells
demonstrated a biphasic response to the synthetic androgen,
R1881 (Figure 1). Growth was stimulated by B50% at 10
 10Mi n
LP-LNCaP cells and inhibited by 50% at 10
 9M in HP-LNCaP
cells. The HP-LNCaP cell proliferation was stimulated in a biphasic
manner, although the dose response curves were shifted 3-log to
the left (Figure 1). Thus, HP-LNCaP cells were stimulated by 50%
at 10
 13M. Proliferation was inhibited at concentrations above
10
 10M. These results suggests that HP-LNCaP cells are hyper-
sensitive to androgens and can respond to very low levels of
androgens, thus contributing to their apparent androgen indepen-
dence. These conclusions are supported by our previous observa-
tion that AR levels were increased in HP-LNCaP cells compared
with LNCaP cells (Schayowitz et al, 2008). However, the absolute
values differ between the different assay systems used in the
different studies.
The effects of an anti-androgens and mTOR inhibition
on growth of LNCaP tumours
The effect of treatment with AR and mTOR inhibitors was
compared with the addition of an mTOR inhibitor to bicalutamide
therapy, as tumours progressed on the anti-androgens. A total of
40 male SCID mice were inoculated with LNCaP cells and
monitored weekly for tumour formation. When tumours reached
500mm
3, mice were then grouped so that tumour volumes were
not significantly different (P¼0.66) and treated with bicalutamide
(100mgkg
 1 q.d. s.c.) or everolimus (2.5mgkg
 1 every 2 weeks
p.o.). When tumours had doubled in volume (tumour progression)
on day 7, animals in the bicalutamide group were subgrouped
(n¼10) by equal tumour volume and continued on anti-androgen
only or administered everolimus (2.5mgkg
 1 every 2 weeks p.o.)
in addition to bicalutamide (100mgkg
 1 q.d. s.c.).
As seen in Figure 2, tumour growth was controlled in the group
administered bicalutamide plus everolimus, whereas tumours
continued to grow during treatment with bicalutamide and
everolimus alone. Inhibition of tumour growth in the combination
treatment group was maintained for over 50 days.
Animals in the control and bicalutamide group were monitored
for over 26 days, the everolimus group for over 33 days, and mice
treated with bicalutamide plus everolimus were studied for
65 days. Linear mixed-effects models were used to analyse the data.
Random effects for intercept and slope at the tumour level nested
within a mouse were used to fit the model. Data on tumour volume
were log transformed to satisfy the assumptions of the linear
mixed-effects models. There were no differences in average tumour
volume on day 0 across treatment groups; P¼0.66. The average
tumour volume on day 7 was not different between mice that
stayed on bicalutamide and the group administered everolimus in
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Figure 1 The effect of androgen on LNCaP and HP-LNCaP cell lines.
Cell lines were treated with increasing concentrations of R1881 and
assayed on day 8 using the MTT assay as described in Materials and
Methods. Cell stimulation is expressed as percent control compared with
vehicle-treated control (mean±s.e.).
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Figure 2 The effect of bicalutamide, everolimus, and bicalutamide plus
everolimus on the growth of LNCaP xenografts. Each mouse received s.c.
inoculation at one site in each flank with 100ml of LNCaP cells suspended
in Matrigel. On tumour formation, mice were grouped and injected daily
with vehicle, bicalutamide (n¼20) (100mgkg
 1 q.d. s.c.) or everolimus
(n¼10) (2.5mgkg
 1 every 2 weeks p.o.). Tumour measurements began at
B500mm
3 and tumour volumes were measured biweekly. After disease
progression (tumour volume doubling), the bicalutamide (n¼20) group
was split into bicalutamide (n¼10) (100mgkg
 1 q.d. s.c.) and bicalutamide
plus everolimus (n¼10) (100mgkg
 1 q.d. s.c. þ 2.5mgkg
 1 every
2 weeks p.o.). Everolimus plus bicalutamide was significantly different
(Po0.04) from all other treatments and control.
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saddition to bicalutamide; P¼0.59. By day 26, the growth rates
between bicalutamide plus everolimus and control (Po0.0001) or
bicalutamide (Po0.0001) were significantly reduced. Animals treated
with everolimus alone, compared with everolimus added to
bicalutamide, also had statistically different growth rates (P¼0.04).
The results suggest that in the LNCaP xenograft model, the
addition of everolimus to bicalutamide treatment of resistant
tumours was more effective than either drug alone, and restored
the sensitivity of tumours to anti-androgen therapy.
The effects of anti-androgens on the expression of proteins
in STPs in HP-LNCaP tumours
We sought to determine the molecular impact of the anti-androgen
treatment over time in a CRPC model. For this investigation, we
analysed tumours collected at the same time points. A total of 30
male SCID mice were inoculated with HP-LNCaP cells. Measurable
tumours formed in B4 weeks after inoculation. Mice were then
grouped (n¼15) and were treated with vehicle (control) or
bicalutamide (100mgkg
 1 q.d. s.c.), and tumours were measured
weekly (Figure 3A). Mice (n¼5) with equal tumour volumes were
isolated at three different time points (2, 3, and 4 weeks) and killed.
Tumours were homogenised and prepared for protein analysis as
described in Materials and Methods.
Tumours of mice treated with anti-androgens were minimally
responsive as expected, as these mice were inoculated with
androgen-resistant cells (Figure 3A). There was an increase in
expression of proteins in the signalling pathways over time
in control and treated groups. By 4–6 weeks, all proteins measured
in the signalling pathways were increased. Additionally, bicaluta-
mide treatment induced increased expression of p-Akt, p-P70S6K,
and p-PS6 faster than in control mice. Changes in expression of
p-HER2, p-MAPK, and p-mTOR at 4 weeks (data not shown) were
about the same in control and bicalutamide-treated tumours.
Serum was also collected for PSA analysis. As in tissue, serum PSA
levels increased after 4 and 6 weeks compared with levels at
2 weeks in control mice. However, PSA levels in the serum, but not
tissue levels, were greatly reduced at all time periods in the
bicalutamide-treated group compared with controls (Figure 3C).
These results suggest that serum PSA level did not reflect PSA
levels in the tumour tissue or the growth of tumour.
The effect of anti-androgens and mTOR inhibitor on
HP-LNCaP xenografts
The rationale for this in vivo investigation was based on our
previously described in vitro findings, which suggested that, unlike
bicalutamide, VN/124-1 is effective in hormone-dependent and
CRPC models (Schayowitz et al, 2008). VN124-1 may also be more
effective in blocking tumour growth in the CRPC model, in
combination with mTOR inhibition (Schayowitz et al, 2008).
A total of 30 male SCID mice were inoculated with HP-LNCaP
cells. Approximately 4 weeks later, on tumour formation, mice
were divided into six groups (n¼5) and treatment was initiated.
The six groups included control, VN/124-1, bicalutamide,
everolimus, bicalutamide plus everolimus, and VN/124-1 plus
everolimus.
Control tumours grew rapidly and mice were killed 27 days after
the start of the treatment (Figure 4A). VN/124-1 (50mgkg
 1 b.i.d.
s.c.) was effective for 15 days, demonstrating a slower trend in
tumour growth compared with control. However, after day 15,
tumours had increased growth rates and mice were killed at day 36.
Everolimus (2.5mgkg
 1 every 2 weeks p.o.) was effective in
reducing tumour volume for the first 30 days of the experiment,
after that tumour growth was rapid and exponential. Dual
inhibition of bicalutamide plus everolimus was more effective
than either bicalutamide or everolimus alone at day 35 (Figure 4A).
However, comparable with all other treatment groups, once
treatment failed, tumour growth was rapid. The bicalutamide plus
everolimus treatment group had a tumour volume over 300% at
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Figure 3 (A) The effect of bicalutamide on the growth of HP-LNCaP xenografts. Each mouse received s.c. inoculation at one site in each flank with 100ml
of HP-LNCaP cells suspended in Matrigel. On tumour formation, mice were grouped and injected daily with vehicle (n¼15) or bicalutamide (n¼15)
(100mgkg
 1 q.d. s.c.). Measurements began at B400mm
3 and tumour volumes were measured weekly. Five mice from each group were isolated and killed
at weeks 2, 3, and 4 for tumour and PSA analysis. Tumour growth rates were not significantly different between bicalutamide treatment and control groups.
(B) Expression of signalling proteins in tumour lysates from HP-LNCaP xenografts. Mice described above in A were treated with vehicle (n¼10) and
bicalutamide (n¼10). Tumours were collected at weeks 2, 3, and 4 of treatment. Western immunoblotting analysis is described in Materials and Methods.
(C) Serum PSA levels of HP-LNCaP xenografts. Total PSA ELISA from the serum of HP-LNCaP xenografts treated with vehicle or bicalutamide for 2, 3, or 4
weeks. The experimental protocol is described in Materials and Methods. The PSA values for bicalutamide-treated mice were statistically significantly
different from controls at all weeks of treatment (Po0.005).
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sday 41 (Figure 4). Inhibition of tumour growth with VN/124-1 plus
everolimus was comparable with bicalutamide plus everolimus for
the first 36 days of treatment. However, whereas tumours became
resistant to the bicalutamide plus everolimus therapy, they
remained sensitive to VN/124-1 plus everolimus. Tumour volumes
were o750mm
3 after 43 days at termination of the experiment
(Figure 4A). All treatments were well tolerated and there were no
changes in body weight of the treated animals over the duration of
the experiment.
For statistical analysis, animals in the control group were
monitored over 29 days. In the VN/124-1 and bicalutamide groups,
tumours were measured for 37 days. The three groups receiving
everolimus administration were studied for 43 days. The tumour
growth rate (slope) was compared between the controls and each
of the five treatment groups. The growth curves were estimated
over 29 days, but there were no differences found in growth rate
among these groups. However, pairwise comparisons of mean
tumour volume on days 29 and 43 demonstrated a statistically
significant difference between VN/124-1 plus everolimus and
everolimus (Po0.003) and also bicalutamide (Po0.0001). There-
fore, the addition of VN/124-1 to everolimus therapy proved to be
superior to everolimus therapy alone in the HP-LNCaP model.
There was no increase in tumour growth after day 25 in the
VN/124-1 plus everolimus-treated group (Figure 4A).
Serum and tumour PSA levels were also analysed. As expected,
PSA concentrations in serum were significantly lower than in the
tumour tissue. Mean PSA in serum was 8.36ngml
 1 and
454.4ngml
 1 in tissue from the control mice. Serum PSA after
VN/124-1 treatment was 4.8ngml
 1 compared with bicalutamide
and everolimus values of 7.4ngml
 1 and 6.7ngml
 1, respectively.
The mean serum PSA levels from the VN/124-1 plus everolimus
treatment group were undetectable. However, the mean PSA level
in tissue (214.1ngml
 1), in the combination of VN/124-1 plus
everolimus group, was also statistically significantly lower than all
other treatment groups.
On termination of treatment, mice were killed, tumours were
removed, and lysed in preparation for western immunoblotting.
Compared with control mice, treatment with bicalutamide
increased expression of p-HER2 (1.4-fold), p-MAPK (3-fold),
p-mTOR (2.2-fold), and p-P70S6K (4-fold) (Figure 4B). Interestingly,
bicalutamide reduced IGF-1R expression significantly, compared
with control and VN/124-1. VN/124-1 tumours demonstrated
increase in growth factor signalling with an increase in expression
of IGFR1 (6.9-fold), p-HER2 (1.9-fold), p-MAPK (3-fold), p-mTOR
(1.6-fold), p-P70S6K (2.6-fold), and p-PS6 (1.2-fold) (Figure 4B).
The AR protein expression was increased in these groups,
consistent with increased sensitivity to androgens. Everolimus
treatment resulted in a 90% decrease in p-mTOR. However, there
were increases in both up- and downstream proteins, including
IGFR1, p-HER2, p-MAPK, p-P70S6K, and p-PS6. The combination
therapy of bicalutamide plus everolimus reduced IGFR1 (100%),
p-Akt (25%), p-mTOR (25%), and p-P70S6K (25%), but increased
expression of p-HER2 (120%), p-MAPK (300%), p-PS6 (20%), and
AR (80%) (Figure 4B). Tumour growth was well controlled by VN/
124-1 plus everolimus, and this combination resulted in reduced
expression of most proteins. Thus, dual inhibition resulted in a
decrease of p-HER2 (100%), p-Akt (40%), p-mTOR (97%),
p-P70S6K (40%), and p-PS6 (100%) downstream of mTOR, as
well as AR (100%) (Figure 4B). The IGFR1 was slightly increased
compared with control, but lower than the high level due to
VN/124-1 treatment alone. The p-MAPK was increased by all
treatments compared with control. The increase in p-MAPK due to
anti-androgen therapy is consistent with in vitro findings
(Schayowitz et al, 2008).
DISCUSSION
Lack of effective treatment of CRPC represents a significant
problem in current management of PCa. Despite initial responses
to hormonal therapy, nearly all advanced PCa patients eventually
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Figure 4 (A) The effect of bicalutamide, VN/124-1, everolimus,
bicalutamide plus everolimus, and VN/124-1 plus everolimus on the
growth of HP-LNCaP xenografts. Each mouse received s.c. inoculation at
one site in each flank with 100ml of LNCaP cells suspended in Matrigel. On
tumour formation, mice were grouped and injected daily with vehicle
(n¼5), bicalutamide (100mgkg
 1 q.d. s.c.; n¼5), VN/124-1 (50mgkg
 1
b.i.d. s.c.; n¼5), everolimus (2.5mgkg
 1 every 2 weeks p.o.; n¼5),
bicalutamide (100mgkg
 1 q.d. s.c.) þ everolimus (2.5mgkg
 1 every
2 weeks p.o.) (n¼5) or VN/124-1 (50mgkg
 1 b.i.d. s.c.) þ everolimus
(2.5mgkg
 1 every 2 weeks p.o.) (n¼5). Measurements began at
B250mm
3 and tumour volumes were measured biweekly. For clarity,
the s.e. bars have been omitted, but full statistical analysis was performed
on tumour measurements. Pairwise comparisons on days 29 and 43 were
significantly different (Po0.03) between everolimus and VN/124-1 plus
everolimus. There was no significant difference between everolimus plus
bicalutamide and everolimus plus VN/124-1. (B) Expression of signalling
proteins from HP-LNCaP xenografts. Tumours were collected at autopsy
from mice described above in A. Animals were treated with vehicle (n¼5),
bicalutamide (n¼5), VN/124-1 (n¼5), everolimus (n¼5), bicalutamide
plus everolimus (n¼5), or VN/124-1 plus everolimus (n¼5). Western
immunoblotting analysis of tumour lysates is described in Materials and
Methods. Representative blots are shown.
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sfail treatment, as tumours become resistant. This investigation was
designed to understand the molecular mechanisms that enable
androgen-dependent PCa cells to progress to CRPC. We also sought
to determine whether blocking the resistance pathway would restore
sensitivity to standard anti-androgens and/or to our novel agent
VN/124-1. Improved understanding of the interaction between the
AR and growth factor signalling could yield a better strategy for
treating disease progression, which may delay, re-sensitise, or prevent
CRPC. The data suggest that increased sensitivity to androgens and a
compensatory cross-talk mechanism between the AR and mTOR
could have a role in the progression to androgen independence. In the
two models used here, resistance to androgen deprivation was
developed in vitro in HP-LNCaP cells and in vivo in the LNCaP
tumours with anti-androgen treatment. As shown in Figure 2, LNCaP
tumours were resistant to bicalutamide after 7 days. However, when
everolimus was added to the anti-androgen therapy at 7 days, tumour
growth was effectively inhibited. Thus, the addition of everolimus to
bicalutamide treatment of resistant tumours significantly decreased
growth rate and tumour volume compared with single-agent
bicalutamide (P¼0.0001) or everolimus (P¼0.04). Additionally, in
the HP-LNCaP xenograft model (Figure 4A), dual inhibition from the
beginning with everolimus (5mgkg
 1 q.w. p.o.) plus VN/124-1
(100mgkg
 1 q.d. s.c.) significantly (P¼0.03) reduced tumour
v o l u m e sa n dg r o w t hr a t e sc o m p a r e d with single-agent everolimus.
Furthermore, growth trends indicate that VN/124-1 plus everolimus
was more effective than bicalutamide plus everolimus. Although PSA
levels in tumour tissue were higher than in serum, nevertheless, PSA
levels in serum and tissues were reduced only by VN/124-1 plus
everolimus, consistent with tumour growth measurements, and
indicate the greater anti-tumour efficacy of VN/124-1 than bicaluta-
mide. It is of note that, although serum levels were reduced to
undetectable levels, tissue levels were still measurable, consistent with
incomplete tumour suppression.
VN/124-1 inhibits androgen synthesis, as well as binds to the AR
and causes its downregulation (Vasaitis et al, 2008). Inhibition of
androgen synthesis, resulting in AR instability in the presence of
everolimus, may have contributed to the greater efficacy of the
combination of everolimus and VN/124-1 over everolimus and
bicalutamide in the intact mice used here. Nevertheless, VN/124-1
alone did not decrease AR levels in the HP-LNCaP tumours.
However, the tumours were collected at autopsy and were clearly
resistant, very large, and actively growing on treatment with
VN/124-1. This is consistent with the AR still being present in the
HP-LNCaP-resistant tumours. In tumours treated with VN/124-1
in combination with everolimus, AR was markedly reduced and
tumour growth inhibited.
In vivo findings also demonstrate that inhibition of AR via
bicalutamide or VN/124-1 increases the expression and activation
of several growth factor signalling proteins. Compensatory cross-
talk was evident by changes in proteins in AR, the MAPK, and
P13K/Akt/mTOR pathways, Thus, inhibition of mTOR increased
AR protein expression in vitro as well as in vivo (Schayowitz et al,
2008). Furthermore, inhibition of AR resulted in increased
expression of IGFR1, p-HER2, and p-mTOR in vivo. We found
that serum PSA levels, but not tissue levels, were suppressed by
bicalutamide and VN/124-1, although tumour growth was not
inhibited. This suggests that tissue PSA may reflect tumour growth
more accurately, and that only a portion of the PSA produced
enters circulation. It is also possible that AR-regulated PSA is still
responsive to anti-androgens, whereas tumour growth is indepen-
dent of androgens and is responsive to other signalling pathways
such as mTOR.
Our results indicate that blockade of AR with anti-androgens
and of mTOR with everolimus improved sensitivity to these agents.
Although others (Kaarbø et al, 2010) have found that the PI3K
pathway is increased in PCa, there was little effect of the anti-
androgens or everolimus on PI3K expression. However, the
combination of VN/124-1 and everolimus significantly reduced
AR, indicating cross-talk between these signalling pathways.
Although the inhibition of AR and signal transduction proteins
with bicalutamide plus everolimus is effective, treatment with
VN/124-1 in combination with everolimus was superior in main-
taining tumour growth suppression in the HP-LNCaP xenograft. This
is consistent with previous findings that bicalutamide is less effective
than VN/124-1 as single-agent therapy, (Schayowitz et al, 2008).
In summary, our studies show that interaction between the AR
and mTOR pathways appears to be involved in tumour progres-
sion in the xenograft models. There is an increase in signal
transduction protein expression as tumours progress on anti-
androgen therapy and in control tumours that are actively
growing. Bicalutamide and everolimus treatment reduced tumour
growth to some extent in comparison with that of control tumours
in the resistant models. However, by combining mTOR inhibition
with an anti-androgen to block both the pathways from the
beginning, tumour growth was statistically significantly reduced
compared with the effect of these drugs alone in the LNCaP and
HP-LNCaP xenografts. Thus, there may be value in using an mTOR
inhibitor in combination with an AR downregulator such as
VN/124-1. VN/124-1 in combination with an mTOR inhibitor may
reduce AR levels and thereby delay transition to growth factor
receptor signalling and hormone resistance. Although everolimus
in combination with bicalutamide has not been found to be
effective in PCa patients (Buckle et al, 2010), our findings suggest
that the combination of everolimus with VN/124-1 may be effective
in resistant disease, based on the more complete inhibition of AR
and mTOR signalling. Improved understanding of the interaction
between the AR and alternate signalling pathways could yield a
better strategy for treating tumour progression that may delay,
re-sensitise, or prevent CRPC.
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